Conba: 11 subsidiary drugs proposed for national organized centralized procurement and continued purchasing

K-LinePoet · 2026-02-28T11:06:33+00:00

Conba Pharmaceutical announced that its subsidiary participated in the national centralized procurement and was awarded contracts for 11 types of medicines, including Tamsulosin Hydrochloride. The expected sales revenue in 2024 is 385 million yuan, accounting for 5.91% of operating revenue; and in the first three quarters of 2025, the projected revenue is 296 million yuan, accounting for 5.95% of operating revenue.

K-LinePoet

2026-02-28 11:06:33

Abstract generation in progress

Conba Pharmaceutical Announcement: Subsidiaries Hangzhou Conba Pharmaceutical Co., Ltd. and Zhejiang Jinhua Conba Biopharmaceutical Co., Ltd. participated in the continuation procurement application for products whose contracts expired in the 1st-8th batches of the national organized centralized procurement. The selected products for this continuation procurement include 11 medicines such as Salbutamol Hydrochloride Extended-Release Capsules, Piperacillin Sodium and Tazobactam Sodium for Injection, and Pantoprazole Sodium Enteric-Coated Tablets. The total sales revenue from these 11 selected medicines in the 2024 centralized procurement is 385 million yuan, accounting for 5.91% of the company’s 2024 operating revenue of 6.515 billion yuan; in the first three quarters of 2025, the total sales revenue from centralized procurement is 296 million yuan, accounting for 5.95% of the company’s operating revenue of 4.976 billion yuan during the same period.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.